

Consolidated Financial Results for FY2017

Consolidated Subsidiaries: 2

ASKA Pharmaceutical Co., Ltd. / ASKA Animal Health Co., Ltd.

	FY2016		FY2017		YoY
	Apr. 2016-Mar. 2017		Apr. 2017-Mar. 2018		
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	48,527	100.0%	48,944	100.0%	100.9%
Cost of Sales	29,614	61.0%	30,059	61.4%	101.5%
Gross Profit	18,913	39.0%	18,884	38.6%	99.8%
Selling, General and Administrative Expenses	17,119	35.3%	16,060	32.8%	93.8%
Operating Income	1,793	3.7%	2,824	5.8%	157.5%
Profit Attributable to Owners of Parent	2,944	6.1%	2,388	4.9%	81.1%

Forecast of Consolidated Financial Results for the FY2017

	FY2017		FY2018	
	Apr. 2017-Mar. 2018		Apr. 2018-Mar. 2019	
	Millions of Yen	Ratio	Millions of Yen	Ratio
Net Sales	48,994	100.0%	49,000	100.0%
Operating Income	2,824	5.8%	1,000	2.0%
Profit Attributable to Owners of Parent	2,388	4.9%	1,000	2.0%

Sales of Main Products

(Billions of yen)

Therapeutic Category	Products	FY2016 Actual	FY2017 Actual	FY2018 Forecast
Antihypertensive agent	CANDESARTAN*	12.75	13.23	11.73
Thyroid hormone	THYRADIN	5.45	4.91	5.52
Hyperlipidemic agent	LIPDIL	4.41	4.29	3.38
LH-RH derivative	LEUPRORELIN	3.84	4.16	4.54
Antihypertensive agent	AMLODIPINE	1.67	1.62	1.37
Poorly absorbable antimicrobial agent	RIFXIMA	0.14	1.06	2.94

※ Including CANDESARTAN formulation's sales